GLP-1 Weight‑Loss Drugs May Extend Lifespan, Researchers Say

Scientists are investigating whether drugs that promote weight loss, such as the GLP‑1 receptor agonist semaglutide (the active ingredient of Ozempic), could also lengthen human life. A preliminary study of people living with HIV who received semaglutide for eight months showed signs of slower biological aging based on blood biomarkers. Lead researcher Michael Corley of the Stein Institute for Research on Aging highlighted the need for more data before drawing firm conclusions.

GLP‑1 drugs are already known to improve metabolic health, lower blood‑sugar levels, aid weight loss, and reduce the risk of cardiovascular disease and diabetes—two leading global causes of death. Experts suggest that these benefits might translate into increased life expectancy, possibly by reducing chronic inflammation and other aging‑related pathways. However, they warn that reliable evidence is lacking for healthy individuals, and potential side effects such as muscle loss and reduced bone density could offset any longevity gains. Ongoing clinical trials aim to clarify the drugs' impact on aging, inflammation, muscle strength and mobility.